What is the appropriate oral terbinafine dose and treatment duration for a pediatric patient with tinea unguium (onychomycosis)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Terbinafine Dosing for Pediatric Tinea Unguium

For pediatric patients with tinea unguium (onychomycosis), terbinafine is dosed weight-based: 62.5 mg daily for children <20 kg, 125 mg daily for 20-40 kg, and 250 mg daily for >40 kg, given for 6 weeks for fingernail infections and 12 weeks for toenail infections. 1

Weight-Based Dosing Algorithm

The British Association of Dermatologists guidelines provide clear, evidence-based dosing for children ages 1-12 years:

  • <20 kg body weight: 62.5 mg once daily
  • 20-40 kg body weight: 125 mg once daily
  • >40 kg body weight: 250 mg once daily

Duration by infection site:

  • Fingernail onychomycosis: 6 weeks
  • Toenail onychomycosis: 12 weeks 1

Important Clinical Considerations

Terbinafine is the preferred first-line agent over itraconazole for pediatric dermatophyte onychomycosis, despite being unlicensed for use in children. 1 The FDA label confirms that safety and efficacy have not been formally established in pediatric patients with onychomycosis 2, but extensive clinical experience supports its use.

Mandatory Monitoring

Obtain baseline laboratory tests before initiating therapy:

  • Liver function tests (AST, ALT)
  • Complete blood count with differential 1

This monitoring is particularly critical in pediatrics given the off-label nature of use. The guidelines emphasize this requirement specifically for pediatric patients.

Key Safety Warnings

Hepatotoxicity: Liver failure requiring transplantation or resulting in death has occurred with oral terbinafine. Discontinue immediately if clinical signs of liver disease develop (persistent nausea, anorexia, fatigue, jaundice, right upper quadrant pain, dark urine). 2

Taste and smell disturbances: Can be severe, prolonged, or permanent. Discontinue if these occur. 2

Neutropenia: Severe cases reported. Stop therapy if neutrophil count drops to ≤1,000 cells/mm³. 2

Alternative Agents (Second-Line)

If terbinafine is contraindicated or not tolerated:

Itraconazole (pulse therapy):

  • 5 mg/kg/day for 1 week per month
  • 2 pulses for fingernails, 3 pulses for toenails
  • Take with food for optimal absorption 1

Fluconazole:

  • 3-6 mg/kg once weekly
  • 12-16 weeks for fingernails, 18-26 weeks for toenails 1

Common Pitfalls to Avoid

  1. Treating without mycological confirmation: Other conditions (psoriasis, traumatic nail dystrophy) can mimic onychomycosis. Always confirm diagnosis with KOH preparation or fungal culture before initiating systemic therapy. 3

  2. Inadequate treatment duration: The full 12-week course for toenails is essential. Shorter durations significantly reduce cure rates—studies show 40% cure with 6 weeks versus 71% with 12 weeks. 4

  3. Missing family screening: Onychomycosis and tinea pedis are contagious. Examine and treat all infected family members simultaneously to prevent reinfection. 1

  4. Ignoring drug interactions: Terbinafine is a potent CYP2D6 inhibitor. Review all concurrent medications, particularly those metabolized by CYP2D6. 2

  5. Using higher doses without evidence: A 500 mg dose in adults showed no additional benefit over 250 mg 5, and there is no pediatric data supporting doses above the weight-based recommendations.

Food Administration

Terbinafine can be taken with or without food—food increases absorption by less than 20%, which is not clinically significant. 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.